CompletedPhase 2

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

United States460 participantsStarted 2009-09

Plain-language summary

The purpose of the study is to evaluate efficacy and safety of arbaclofen placarbil (XP19986) versus placebo as adjunctive therapy in subjects with troublesome GERD symptoms despite therapy with approved doses of a Proton Pump Inhibitor (PPI).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. confirmed diagnosis of GERD by a gastroenterologist
✓. minimum of 3 months of GERD symptoms prior to screening.
✓. currently taking an FDA approved dose of PPI therapy for symptomatic GERD for at least 4 weeks prior to screening
✓. experienced partial relief of GERD symptoms while receiving approved dose and regimen of PPI therapy
✓. experienced GERD symptoms, defined as heartburn (with or without regurgitation or other GERD symptoms) on ≥ 3 days during the week prior to screening

Exclusion criteria

✕. evidence of erosive esophagitis or erosive gastritis on upper gastrointestinal endoscopy during screening
✕. has not experienced any GERD symptom improvement after an adequate course of PPI treatment (at least 2 weeks)
✕. unstable or severe medical condition

What they're measuring

Heartburn Episodes

Timeframe: 6 weeks

Trial details

NCT IDNCT00978016

SponsorXenoPort, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-12

View on ClinicalTrials.gov More Gastroesophageal Reflux Disease trials